RT journal article
T1 Modifications of CD4 T cells, CD4/CD8 ratio and serum levels of soluble CD14 in HIV-HCV-coinfected patients after sustained HCV response induced by direct-acting antiviral agents: influence of liver cirrhosis
A1 Girón Ortega, José Antonio
A1 Márquez Coello, María de las Mercedes
A1 Gutiérrez Saborido, Daniel
A1 Arizcorreta Yarza, Ana
A1 Cuesta Sancho, Sara
A1 Girón González, José Antonio
A2 BiomedicinaBiotecnología y Salud Pública
A2 Medicina
K1 HIV infection
K1 Hepatitis C virus
K1 CD4 T cells
K1 CD8 T cells
K1 CD4/CD8 ratio
K1 Soluble CD14
K1 Direct-acting antiviral agents
K1 Sustained viral response
AB To analyze the modifications of CD4 T cell, CD4/CD8 ratio, and serum levels of soluble CD14 (sCD14) in HIV/HCV-coinfected patients after treatment with direct anti-HCV antiviral agents. Consecutive cases of HIV/HCV-coinfected patients, attended at the University Hospital, who achieved sustained virological responses with interferon-free hepatitis C antiviral drugs, were analyzed. Thirty-five percent of patients (n = 39) had been diagnosed with liver cirrhosis. The evaluation criteria were changes in CD4 T-cell counts and percentages and inflammation (measured by serum sCD14 levels) or immune activation indexes (determined by CD4/CD8 ratio) from beginning anti-HCV therapy to 12 months later. One hundred twelve patients were included (87% male; median age, 54 years; median time from the infection diagnosis, 22 years; previous drug users, 87%). Significant increases in CD4 T cell count and percentage were detected only in individuals without liver cirrhosis. No significant differences in CD4/CD8 ratios or sCD14 levels were observed in patients with or without cirrhosis. The proportion of patients with less than 500 CD4 T cell/mm3 before therapy who achieved more than 500 CD4 T cell/mm3 after it increased only in the group without liver cirrhosis. The finding that CD4 T cell count and percentage were improved only in patients without liver cirrhosis supports the idea that treatment against HCV in HIV/HCV-coinfected patients is needed in the early phases of liver disease.
PB SPRINGER
SN 1435-4373
YR 2021
FD 2021
LK http://hdl.handle.net/10498/33879
UL http://hdl.handle.net/10498/33879
LA eng
NO Secretaría General de Investigación, Desarrollo e Innovación en Salud, Junta de Andalucía, Iniciativa Territorial Integrada 2014-2020 para la provincia de Cádiz (No PI-0076-2017), Spain. Co-financed by FEDER (Fondo Europeo de Desarrollo Regional).
DS Repositorio Institucional de la Universidad de Cádiz
RD 13-nov-2026